Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Sunil Babu"'
Autor:
Vernon K. Sondak, Andrew Poklepovic, Nikhil I. Khushalani, Jason J. Luke, Sunil Babu, Sigrun Hallmeyer, Zeynep Eroglu, Mario R. Velasco, Emily F. Higgs, Bruce Brockstein, Daniel J Olson, Thomas Krausz, Madhuri Bajaj, Timothy Carll, Riyue Bao, Jose Lutzky, Theodore Karrison, Brian W. Labadie, Thomas F. Gajewski, Yuanyuan Zha
Publikováno v:
J Clin Oncol
PURPOSE Combination of antiprogrammed cell death protein-1 (PD-1) plus anti–cytotoxic T-cell lymphocyte-4 (anti-CTLA-4) immunotherapy shows greater response rates (RRs) than anti-PD-1 antibody alone in melanoma, but RR after initial anti-PD-1 and p
Autor:
Ang Li, Jason C. Chandler, Davey B. Daniel, Félix Couture, Sunil Babu, Vijay Gunuganti, Maen A. Hussein, Robert M. Jotte, Samer Kasbari, Michael McCleod, Edward B. Garon, Justin N. Baker, Nivedita Aanur, Lawrence H. Einhorn, Leora Horn, Ben C. Creelan, Petros Nikolinakos, George P. Keogh, David R. Spigel, Craig Reynolds, Natasha B. Leighl, David M. Waterhouse, George R. Blumenschein
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 38(33)
PURPOSE Limited data exist on the optimal duration of immunotherapy, including for non–small-cell lung cancer (NSCLC). We present an exploratory analysis of CheckMate 153, a largely community-based phase IIIb/IV study, to evaluate the impact of 1-y
Autor:
Craig W. Reynolds, Paul Thurmes, Wen Hong Lin, Sunil Babu, Jin Zhu, David R. Spigel, Robert M. Jotte, David M. Waterhouse, Edward B. Garon, Jason C. Chandler, George R. Blumenschein, Alexander I. Spira
Publikováno v:
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 13(5)
Introduction Crizotinib, an anaplastic lymphoma kinase (ALK) inhibitor, is a first-line treatment for ALK translocation–positive advanced non–small cell lung cancer (NSCLC); however, patients eventually progress. Immunotherapies, including the pr
Autor:
James Essell, Roger M. Lyons, Elias J. Jabbour, Ralph V. Boccia, Guillermo Garcia-Manero, Mikkael A. Sekeres, Rami S. Komrokji, Yasmin Abaza, Richard G. Ghalie, Brian Heller, Gail J. Roboz, Philip Kuriakose, Farhad Ravandi, Hagop M. Kantarjian, David Wright, Bertrand Anz, Sunil Babu, Guillermo Montalban-Bravo, Jesus G. Berdeja, Michael B. Maris, James A. Reeves, Amy E. DeZern
BACKGROUND The prognosis of patients with higher risk myelodysplastic syndromes (MDS) remains poor despite available therapies. Histone deacetylase inhibitors have demonstrated activity in patients with MDS and in vitro synergy with azacitidine. METH
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8e6356e38d0b01f064458ed887e76fd3
https://europepmc.org/articles/PMC5432122/
https://europepmc.org/articles/PMC5432122/
Autor:
Kiran Yalamanchili, Rishi Sukhija, William H. Frishman, Wilbert S. Aronow, Sunil Babu, Ravi Kilaru, Stephen J. Peterson
Publikováno v:
Cardiology in review. 14(2)
We investigated the severity of coronary artery disease (CAD) diagnosed by coronary angiography performed because of suspected CAD in 102 persons, mean age 68 years, with rheumatoid arthritis (RA) and in 102 age-matched and sex-matched persons. CAD w